This is essential if a patient is considered to be at higher than average risk (i.e., having a strong family history of breast cancer or personal history of breast cancer, benign breast disease, or inherited BRCA1 and/or BRCA2 mutations). This evidence concerns the gene BRCA2 and breast fibrocystic disease.